Northeast Pharmaceutical Group Co Ltd

Northeast Pharmaceutical Group Co Ltd has a market capitalization of CNY 6.96 billion and a price-to-earnings ratio of 26.78, which is above the industry median for pharmaceutical firms. The company's liquidity position is characterized by a current ratio of 1.15 and a debt-to-equity ratio of 0.45, indicating a moderate level of leverage. Free cash flow stands at CNY 465.22 million, but the company has a negative net cash position after subtracting total debt. Profitability metrics show a return on equity of 4.7% and a return on assets of 2.02%, both of which are below the industry median for pharmaceutical companies. The company's gross profit margin is 34.86%, and its operating margin is 4.44%, suggesting that it is underperforming in terms of cost control and operational efficiency compared to its peers. The company's revenue is primarily concentrated in China, with no significant international exposure disclosed. There is no detailed breakdown of revenue by product segment in the available data, but the company's operations are centered on pharmaceuticals and active pharmaceutical ingredients. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. Capital expenditure is negative at CNY -97.78 million, indicating a reduction in investment in physical assets. The company's risk assessment highlights a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. Recent filings and transcripts do not indicate any major strategic shifts or regulatory challenges. The company's 10-K filing does not disclose any material events that would significantly alter its business model or risk profile in the near term.